Haemorrhagic Stroke Treatment Market Size and Share - Outlook Report, Forecast Trends and Growth Analysis (2024-2032)

Haemorrhagic Stroke Treatment Market Outlook

• The market is significantly driven by the growing investments in research and development activities, leading to innovative therapies and improved patient outcomes.
• The rising number of FDA approvals is bolstering market expansion by ensuring faster access to effective treatment therapies.
• Strategic acquisitions by key market players are enabling companies to expand their product portfolios and enhance technological capabilities, driving market growth.

Haemorrhagic Stroke Treatment Market Overview 

In haemorrhagic stroke, the brain suffers from severe damage causing compromised ability of body movement (depending on the affected region). Long-term outcome depends on the extent of brain damage and the early treatments among several other factors. However, taking precautionary measures and seeking early treatment can help minimise stroke-related brain damage. Hemorrhagic strokes occur when blood vessels in the brain rupture or leak, causing bleeding in or around the brain, accounting for about 20% of all strokes. 

There are several kinds of hemorrhage including subarachnoid hemorrhage (SAH) referring to bleeding around the brain. It is often caused by the rupture of an aneurysm on the brain’s surface. Intracerebral hemorrhage (ICH) involves bleeding into the brain itself, commonly triggered by high blood pressure, making timely medical intervention crucial for recovery.

Haemorrhagic Stroke Treatment Market Growth Drivers

Rising Cases of Stroke Driving Market Growth

The market is primarily driven by the rising incidence of haemorrhagic strokes among people, especially young adults, and elderly individuals. As per the data released by the Centers for Disease Control and Prevention (CDC), it is estimated that more than 750,000 strokes take place in the USA every year. About 87% of all strokes are ischemic strokes, in which blood flow to the brain is blocked.  
The rising numbers are demanding new treatment options and diagnostic solutions to treat and prevent the occurrence of this extremely life-threatening medical condition. 

FDA Approvals to Meet Growing Haemorrhagic Stroke Treatment Market Demand

The market is witnessing significant approvals by the regulatory authorities to bring new and advanced treatments and diagnostic solutions into the market. For instance, in May 2024, the Food and Drug Administration (FDA) granted 510(k) clearance for Heuron ICH, an artificial intelligence (AI)-enabled software that is expected to facilitate timely detection and triage of intracranial hemorrhages.  As per the claims by Heuron, the software provides an 86% sensitivity rate and an 88% specificity rate for intracranial hemorrhage. The FDA approval marks a significant milestone for the company positioning it highly in the United States market, and propelling market growth. 

Haemorrhagic Stroke Treatment Market Trends

Rising Research and Clinical Trials

With the rising cases of haemorrhagic strokes and the unavailability of sufficient treatment options in the market, researchers are increasingly exploring the potential of new treatments and are engaged in the development of effective drugs. With new studies, the scientists are hopeful to conduct more trials and analyse various drugs which may bring a groundbreaking innovation into the market and contribute to enhanced patient outcomes. 

New Product Launches Integrated with AI to Boost Haemorrhagic Stroke Treatment Market Value

The market players are playing a crucial role in market growth as they are expanding their market reach with exclusive product launches in extended regions, supporting the availability of timely and effective treatment options for patients as well as healthcare providers. For instance, in November 2023, Brainomix, an AI-powered medtech solutions company, initiated its United States expansion with the launch of its full suite of FDA-cleared modules in its Brainomix 360 platform for stroke care. The US launch represents a comprehensive platform designed to support clinicians and their imaging-based treatment decisions at all points across the stroke pathway, from simple imaging to more advanced imaging . The platform has state-of-the-art AI algorithms providing real-time interpretation of brain scans enabling timely treatment and transfer decisions for stroke patients.

Strategic Acquisitions to Drive Haemorrhagic Stroke Treatment Market Growth

The market is expected to be influenced by the strategic moves of market players. For instance, in September 2024, Stryker acquired NICO Corporation, a privately held company providing a systematic approach to minimally invasive surgery for tumor and intracerebral haemorrhage (ICH) procedures. The acquisition is poised to strengthen Stryker’s commitment to neurotechnology through tumor and stroke care.  The acquisition is set to expand Stryker’s portfolio dedicated to solutions for tumor resection and the treatment of intracerebral haemorrhage which in turn will enable the company to deliver varied, minimally invasive approaches improving patient outcomes and enhanced patient lifestyles.

Surge in Investment Boosting Treatment Innovation

The market is significantly driven by government investments in research initiatives, advancing healthcare infrastructure, and the development of innovative therapies and medical technologies. For instance, in May 2024, Balt, a medical equipment manufacturer specialising in medical devices designed to treat stroke and other neurovascular diseases, received EUR 4.2 million worth of funding from the French government. The company is involved in the development of a groundbreaking project CICACOILS, for the treatment of hemorrhagic stroke with several French public academic research institutes. 

Haemorrhagic Stroke Treatment Market Segmentation

Market Breakup by Drug Class

• Antihypertensive 
• Anticoagulants 
• Anticonvulsants 
• Others  

Market Breakup by Route of Administration

• Oral 
• Injectable

Market Breakup by Distribution Channel

• Hospital Pharmacy 
• Retail Pharmacy 
• Online Pharmacy 
• Others

Market Breakup by Region

• United States 
• EU-4 and the United Kingdom 
  • Germany 
  • France 
  • Italy 
  • Spain 
  • United Kingdom 
• Japan 
• India 

Haemorrhagic Stroke Treatment Market Share

Segmentation by Route of Administration to Hold a Substantial Share of the Market

The injectable segment leads the market share by route of administration due to the rapid and direct delivery of medications into the bloodstream, ensuring faster therapeutic effects, which is critical in emergency stroke management. Injectable treatments, such as anticoagulants, clotting factor concentrates, and antihypertensives, are preferred in acute care settings where quick intervention is necessary to control bleeding and prevent further brain damage. Additionally, hospitals and stroke centers favour injectable treatments for their effectiveness in stabilising patients during the critical phases of haemorrhagic stroke treatment.

Haemorrhagic Stroke Treatment Market Analysis by Region

The United States leads the regional market share due to its advanced healthcare infrastructure, high prevalence of stroke cases, and significant investments in research and development. The regional dominance is driven by the technologically advanced healthcare infrastructure and the availability of innovative treatment options, such as minimally invasive surgical techniques and advanced pharmaceuticals. Additionally, strong support from government health initiatives and the presence of leading pharmaceutical companies in the region, contribute to the dominance. The high healthcare expenditure and well-established reimbursement policies further drive the growth of the market in the United States.

Leading Players in the Haemorrhagic Stroke Treatment Market

The key features of the market report comprise patent analysis, clinical trials analysis, grants analysis, funding and investment analysis and strategic initiatives by the leading players. The major companies in the market are as follows:

B. Braun Melsungen AG

Established in 1839, and headquartered in Melsungen, Germany, B. Braun Melsungen AG is a leading medical and pharmaceutical company. It offers an extensive portfolio including surgical instruments, infusion therapy, and pain management solutions, focusing on enhancing patient safety and healthcare efficiency.
 
Bayer AG

Founded in 1863 and headquartered in Leverkusen, Germany, Bayer is a global pharmaceutical and life sciences company. Its product portfolio in the healthcare market includes prescription pharmaceuticals, consumer health products, and crop protection solutions, with a focus on innovations in cardiovascular, oncology, and women's health.

Novartis AG

Established in 1996, Novartis is headquartered in Basel, Switzerland. The company is a major player in the global pharmaceutical market, specialising in innovative medicines, generic pharmaceuticals, and eye care products. Its portfolio addresses areas like oncology, immunology, neuroscience, and respiratory conditions.

Pfizer Inc.

Founded in 1849 and headquartered in New York City, Pfizer is a leading biopharmaceutical company. It is renowned for its extensive portfolio in the pharmaceutical market, offering treatments for various medical fields, including oncology, vaccines, internal medicine, and rare diseases, with a strong focus on innovative research.

Merck & Co., Inc.

Established in 1891, Merck & Co., Inc., headquartered in Kenilworth, New Jersey, is a global healthcare company. Its portfolio in the pharmaceutical market includes prescription medicines, vaccines, biologic therapies, and animal health products, with a focus on addressing cancer, infectious diseases, and chronic conditions like diabetes.

Other key players in the market include GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Amneal Pharmaceuticals LLC, Bristol-Myers Squibb Company, Daiichi Sankyo Company, and Boehringer Ingelheim International GmbH.

Key Questions Answered in the Haemorrhagic Stroke Treatment Market

• What was the haemorrhagic stroke treatment market value in 2023? 
• What is the haemorrhagic stroke treatment market forecast outlook for 2024-2032?  
• What is market segmentation based on drug class? 
• How does segmentation by route of administration influence market dynamics?   
• What are the distribution channels in the market? 
• What are the major factors aiding the haemorrhagic stroke treatment market demand?  
• How has the market performed so far and how is it anticipated to perform in the coming years? 
• What are the market's major drivers, opportunities, and restraints?  
• Which country is expected to experience expedited growth during the forecast period?  
• What are the major haemorrhagic stroke treatment market trends?
• Which drug class is expected to dominate the market? 
• Which route of administration will lead the market segment? 
• Which distribution channel will lead the market?
• Who are the key players involved in the haemorrhagic stroke treatment market? 
• What is the patent landscape of the market? 
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?